Nurix Therapeutics, Inc. (NRIX) News
Follow Nurix Therapeutics, Inc. (NRIX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 37 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A Nurix Therapeutics, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:23 PM UTC
M
Nurix Shares Fall 36.9% After Sanofi Discontinues STAT6 Drug Program
EQUITY | Nov 04, 2026, 07:50 PM UTC
L
Sanofi Ends Autoimmune Disease Drug Program
Nurix says Sanofi is ending its program related to drugs for autoimmune diseases.
EQUITY | Nov 04, 2026, 07:01 PM UTC
L
Nurix Says Sanofi Ends Autoimmune Disease Drug Program
Nurix says Sanofi is ending a drug program for autoimmune diseases.
EQUITY | Nov 04, 2026, 07:01 PM UTC
L
Nurix, Sanofi Halt Development of Autoimmune Drug
Nurix and Sanofi have halted development of an autoimmune drug.
EQUITY | Nov 04, 2026, 07:01 PM UTC
M
Sanofi Discontinues Nurix’s SAR448272 Program
Sanofi has decided to end the Phase 1 first-in-human trial and terminate the program. Nurix will no longer be eligible for associated future milestones or royalties, but says its cash runway guidance is unchanged.
EQUITY | Nov 03, 2026, 11:03 PM UTC
M
Nurix Shares Slump 35% After Hours After Sanofi Ends Drug Development
Sanofi notified Nurix Therapeutics that it is discontinuing development of experimental oral drug SAR448272, which it licensed from Nurix.
EQUITY | Nov 03, 2026, 10:58 PM UTC
M
Nurix Shares Fall 34% After Sanofi Ends Drug Development Program
Nurix said Sanofi is terminating a drug development program under the companies’ collaboration agreement. Shares fell 34% to $17.07 in after-hours trading Tuesday.
EQUITY | Nov 03, 2026, 09:56 PM UTC
L
Sanofi ends autoimmune disease drug development program with Nurix
Nurix said Sanofi has discontinued a development program for autoimmune and inflammatory diseases.
EQUITY | Nov 03, 2026, 09:36 PM UTC
M
Sanofi Discontinues Autoimmune Drug Program, Nurix Says
Nurix said Sanofi ended development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties tied to the program.
EQUITY | Nov 03, 2026, 09:32 PM UTC
M
Nurix says cash can fund operations into second half of 2029
EQUITY | Nov 03, 2026, 09:07 PM UTC
L
Sanofi terminates SAR448272 program
Nurix Therapeutics said Sanofi notified the company of its decision to terminate the SAR448272 program.
EQUITY | Nov 03, 2026, 09:06 PM UTC
M
Nurix Says Sanofi Halts Phase 1 Trial of STAT6 Degrader SAR448272
EQUITY | Nov 03, 2026, 09:05 PM UTC
M
Nurix Therapeutics Will Receive No Future SAR448272 Milestones or Royalties
EQUITY | Nov 03, 2026, 09:04 PM UTC
M
Nurix Reports Q3 Revenue of $673.1M and Net Income of $549.8M
Revenue was driven primarily by a $653.2 million license payment from the Roche collaboration. Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 3…
EQUITY | Oct 13, 2026, 10:31 AM UTC
M
Nurix Therapeutics Swings to Profit in Q3 on Roche Collaboration
EQUITY | Oct 12, 2026, 08:15 PM UTC
M
Nurix Therapeutics Reports 3Q Revenue of $673.1 Million
EARNINGS | Oct 12, 2026, 08:06 PM UTC
M
Nurix Therapeutics Reports 3Q Net Income of $549.8 Million
EARNINGS | Oct 12, 2026, 08:05 PM UTC
M
Nurix Therapeutics Reports 3Q EPS of $4.73
EARNINGS | Oct 12, 2026, 08:05 PM UTC
M
Nurix Therapeutics Reports Third-Quarter 2026 Results and Corporate Update
Nurix Therapeutics reported third-quarter 2026 financial results and provided a corporate update.
EQUITY | Oct 12, 2026, 08:05 PM UTC
M
Nurix to report Q3'26 results Oct. 9
Nurix Therapeutics is set to announce Q3'26 results on October 09. Estimates cite revenue and EPS figures for the quarter.
EQUITY | Oct 08, 2026, 11:00 AM UTC
H
Stock Market: Will S&P 500 Open Up or Down Today?
U.S. stock futures are trending slightly lower early Thursday as investors digest hawkish inflation survey data, rising Treasury yields, and reports that the Pentagon is preparing for potential military strikes in Iran.
LIVE | Oct 08, 2026, 06:12 AM UTC
L
Nurix Therapeutics, Inc. (NRIX) Receives $7M Milestone From Pfizer
Nurix Therapeutics will receive a $7M milestone payment from Pfizer under their DACs collaboration, bringing total receipts under the agreement to $82M.Material DetailsContext by AI AnalystThis is incremental validation
NEWS | Sep 29, 2026, 11:09 AM UTC
L
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACsBRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. NASDAQ:NRIX, a clinica
NEWS | Sep 29, 2026, 11:08 AM UTC
L
NRIX: Major Roche deal accelerates BTK degrader's global development and multi-billion dollar potential
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with pivotal trials underway and a strong safety profile supporting broad development in oncology and autoimmune diseases. Additio
NEWS | Sep 14, 2026, 06:49 PM UTC
M
NRIX expansion of BTK degrader backed by Roche partnership
NRIX said its BTK degrader is progressing in CLL, CSU and MS, while a Roche partnership expands indications and provides financial backing. The pipeline also includes STAT6 and IRAK4 degraders with multiple upcoming read
EQUITY | Sep 08, 2026, 08:01 PM UTC
L
Nurix Therapeutics management to participate in September investor conferences
Nurix Therapeutics said company management will participate in upcoming September investor conferences.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
NRIX - Nurix Therapeutics to Participate in Upcoming September Investor Conferences
NRIX - Nurix Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
Nurix Therapeutics appoints Wes Burwell as chief human resources officer
Nurix Therapeutics says it has appointed Wes Burwell as chief human resources officer.
REGULATION | Aug 20, 2026, 11:00 AM UTC
H
Nurix Receives $10M Milestone Payment
Nurix gets $10M for starting a Phase 1 trial
EQUITY | Aug 04, 2026, 11:02 AM UTC
M
Nurix Enrolls First Patient in Phase 3 CLL Trial
Nurix starts Phase 3 trial for leukemia treatment
EQUITY | Aug 04, 2026, 05:00 AM UTC
L
NRIX Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-clas
NRIX Nurix Therapeutics announces hsr clearance of global collaboration with Roche to Co-develop and Co-commercialize potential best-in-class btk degrader bexobrutideg across malignant hematology, immunology and neurolog
EQUITY | Jul 21, 2026, 08:01 PM UTC
H
Nurix Therapeutics price target raised to $34 from $32 at Truist
Truist analyst Gregory Renza raised the firm's price target on Nurix Therapeutics to $34 from $32 and keeps a Buy rating on the shares after its Q2 results. The company's earnings and the firm's follow-up call with the m
EQUITY | Jul 10, 2026, 12:42 PM UTC
L
Nurix Therapeutics reports Q2 EPS (81c), consensus (72c)
Reports Q2 revenue $9.04M, consensus $15.29M. "The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field," said Arthur Sands, president and chief executive officer of Nurix. "O
EQUITY | Jul 09, 2026, 08:08 PM UTC
H
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
EARNINGS | Jul 09, 2026, 08:03 PM UTC
L
Top 3 Health Care Stocks That May Keep You Up At Night In June
As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a
REGULATION | Jun 30, 2026, 12:55 PM UTC
M
12 Health Care Stocks Move
Multiple health care stocks are moving in Thursday's intraday session, with gainers including Atlantic International and SELLAS Life Sciences, and losers including Nano X Imaging and Passage Bio
EQUITY | Jun 25, 2026, 05:05 PM UTC